Development of hepatocellular carcinoma after sustained response to interferon therapy : how long should sustained responders with risk factors be followed?
スポンサーリンク
概要
- 論文の詳細を見る
- 2005-02-01
著者
-
Kasahara Akinori
Department Of General Medicine Osaka University Graduate School Of Medicine
-
Kasahara Akinori
Department Of Gastroenterology And Hepatology Osaka University Graduate School Of Medicine
関連論文
- Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C
- Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance
- Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B
- Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis
- Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C
- Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C
- Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection
- Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
- The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan
- Juvenile hepatocellular carcinoma with congestive liver cirrhosis